Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mdc-WWM
- Development stage
- Preclinical
- Lead developer
- MedinCell
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
mdc-WWM is a preclinical, long-acting injectable contraceptive under development by MedinCell. It utilizes a non-medroxyprogesterone acetate (non-MPA) progestin molecule and is designed for subcutaneous administration using the BEPO technology platform. The formulation is fully bioresorbable and intended to provide contraceptive efficacy for six months per injection. The program aims to deliver an affordable, best-in-class product with global access, particularly targeting emerging economies. Preclinical activities and initial clinical studies are supported by up to $19 million in funding from the Bill & Melinda Gates Foundation[1][2][3][8].
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on mdc-WWM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mdc-WWM.